2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
Diagnosis and treatment of primary aldosteronism
Primary aldosteronism is a common cause of secondary hypertension associated with
excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it …
excess cardiovascular morbidities. Primary aldosteronism is underdiagnosed because it …
[HTML][HTML] Phase 2 trial of baxdrostat for treatment-resistant hypertension
MW Freeman, YD Halvorsen, W Marshall… - … England Journal of …, 2023 - Mass Medical Soc
Background Aldosterone synthase controls the synthesis of aldosterone and has been a
pharmacologic target for the treatment of hypertension for several decades. Selective …
pharmacologic target for the treatment of hypertension for several decades. Selective …
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
This review covers the last 80 years of remarkable progress in the development of
mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of the first …
mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of the first …
JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure―digest version―
H Tsutsui, M Isobe, H Ito, K Okumura, M Ono… - Circulation …, 2019 - jstage.jst.go.jp
Heart Failure Society (JHFS). The working committee for this project includes members and
collaborators involved in the previous versions of the heart failure guidelines and members …
collaborators involved in the previous versions of the heart failure guidelines and members …
Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America: this statement does not …
Type 2 diabetes mellitus is a risk factor for incident heart failure and increases the risk of
morbidity and mortality in patients with established disease. Secular trends in the …
morbidity and mortality in patients with established disease. Secular trends in the …
Evaluation of kidney function throughout the heart failure trajectory–a position statement from the Heart Failure Association of the European Society of Cardiology
W Mullens, K Damman, JM Testani… - European journal of …, 2020 - Wiley Online Library
Appropriate interpretation of changes in markers of kidney function is essential during the
treatment of acute and chronic heart failure. Historically, kidney function was primarily …
treatment of acute and chronic heart failure. Historically, kidney function was primarily …
Клинические рекомендации ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика …
ВЮ Мареев, ИВ Фомин, ФТ Агеев, ЮЛ Беграмбекова… - Кардиология, 2018 - lib.ossn.ru
1–«МНОЦ МГУ им. МВ Ломоносова», 119192, Москва, Ломоносовский пр-кт, д. 27, корп.
10 2–ФГБОУ ВО «ПИМУ» МЗ РФ, 603950, Нижний Новгород, пл. Минина и Пожарского …
10 2–ФГБОУ ВО «ПИМУ» МЗ РФ, 603950, Нижний Новгород, пл. Минина и Пожарского …
[HTML][HTML] 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of …
SM Hollenberg, L Warner Stevenson, T Ahmad… - Journal of the American …, 2019 - jacc.org
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …
decision pathways, health policy statements, appropriate use criteria) to provide members …
Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease
U Kintscher, GL Bakris, P Kolkhof - British Journal of …, 2022 - Wiley Online Library
Mineralocorticoid receptor antagonists (MRAs) are key agents in guideline‐oriented drug
therapy for cardiovascular diseases such as chronic heart failure with reduced ejection …
therapy for cardiovascular diseases such as chronic heart failure with reduced ejection …